1. Home
  2. CWAN vs GKOS Comparison

CWAN vs GKOS Comparison

Compare CWAN & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CWAN
  • GKOS
  • Stock Information
  • Founded
  • CWAN 2004
  • GKOS 1998
  • Country
  • CWAN United States
  • GKOS United States
  • Employees
  • CWAN N/A
  • GKOS N/A
  • Industry
  • CWAN Computer Software: Prepackaged Software
  • GKOS Medical/Dental Instruments
  • Sector
  • CWAN Technology
  • GKOS Health Care
  • Exchange
  • CWAN Nasdaq
  • GKOS Nasdaq
  • Market Cap
  • CWAN 5.3B
  • GKOS 5.4B
  • IPO Year
  • CWAN 2021
  • GKOS 2015
  • Fundamental
  • Price
  • CWAN $18.11
  • GKOS $87.33
  • Analyst Decision
  • CWAN Buy
  • GKOS Strong Buy
  • Analyst Count
  • CWAN 10
  • GKOS 13
  • Target Price
  • CWAN $31.70
  • GKOS $121.46
  • AVG Volume (30 Days)
  • CWAN 4.2M
  • GKOS 826.0K
  • Earning Date
  • CWAN 11-05-2025
  • GKOS 10-29-2025
  • Dividend Yield
  • CWAN N/A
  • GKOS N/A
  • EPS Growth
  • CWAN N/A
  • GKOS N/A
  • EPS
  • CWAN 1.60
  • GKOS N/A
  • Revenue
  • CWAN $551,094,000.00
  • GKOS $432,953,000.00
  • Revenue This Year
  • CWAN $64.64
  • GKOS $28.90
  • Revenue Next Year
  • CWAN $30.03
  • GKOS $25.57
  • P/E Ratio
  • CWAN $11.30
  • GKOS N/A
  • Revenue Growth
  • CWAN 36.68
  • GKOS 26.70
  • 52 Week Low
  • CWAN $17.15
  • GKOS $77.10
  • 52 Week High
  • CWAN $35.71
  • GKOS $163.71
  • Technical
  • Relative Strength Index (RSI)
  • CWAN 34.53
  • GKOS 47.37
  • Support Level
  • CWAN $17.15
  • GKOS $83.77
  • Resistance Level
  • CWAN $18.40
  • GKOS $89.29
  • Average True Range (ATR)
  • CWAN 0.53
  • GKOS 3.01
  • MACD
  • CWAN -0.02
  • GKOS 0.55
  • Stochastic Oscillator
  • CWAN 26.29
  • GKOS 57.25

About CWAN Clearwater Analytics Holdings Inc.

Clearwater Analytics describes its mission as aiming to be the world's most trusted and comprehensive technology platform for the entire investment cycle. Clearwater has historically focused on back-office functions such as investment accounting, but with acquisitions such Enfusion, Beacon, and Bistro, the firm has broadened its focus with front-office and middle-office capabilities. Clearwater primarily serves insurance companies, asset managers, hedge funds, and corporate treasuries. Pro forma for Enfusion, about 76% of Clearwater's revenue is generated in the US.

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Share on Social Networks: